JBIO

Latest SEC Filings & News for JBIO

2 most recent filings and news items mentioning JBIO. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/JBIO/news?limit=20"

Pull JBIO filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

LeadershipJun 26, 2026Neutral

Jade Biosciences appoints Dr. Mark Eisner to Board of Directors

Jade Biosciences, Inc. (JBIO) announced the appointment of veteran biopharmaceutical executive Dr. Mark Eisner to its board of directors. This leadership addition is expected to bolster the company's efforts in advancing its antibody-based autoimmune therapies.

View filing at SEC.gov →

RegulatoryJun 1, 2026Positive

Jade Biosciences presents JADE101 Phase 1 interim data ahead of Phase 2 trial

Jade Biosciences held a conference call on June 1, 2026 to discuss interim Phase 1 data for JADE101, a clinical-stage therapeutic candidate. The company plans to advance to Phase 2 enrollment and potentially Phase 3 registrational studies pending positive results.

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.